Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceutical company, today  announced a partnership between Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, and Libbs Farmaceutica, a leading pharmaceuticals company in Brazil, to launch generic drugs in Brazil, the  world’s sixth most populous country.  

This partnership, which marks the entry of Biocon’s generic formulations into Latin America, builds upon a  successful association with Libbs, which began in 2017 to launch biosimilar Trastuzumab in Brazil. It reflects Biocon’s commitment to make affordable healthcare accessible for patients the world over, by establishing a  strong global presence for its formulations portfolio, either directly or through strategic partnerships. 

As part of the out-licensing deal with Libbs, Biocon Pharma will be responsible for drug development and  manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and  market, subject to approvals from the Brazilian health regulatory agency, ANVISA.  

Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, said, “Expanding our association with Libbs Farmaceutica, a trusted partner, to our generic formulations, will help us establish a firm footing  in Latin America, starting with Brazil. We remain committed to expanding our global presence with high quality and affordable medicines and invest in strengthening capabilities that enable us to serve patients  globally.” 

Abhijit Zutshi, Commercial Head, Global Generics, added, “The partnership with Libbs further builds on  Biocon’s ability to forward integrate its portfolio of complex and differentiated APIs into finished dosages.  The resultant quality, safety and cost advantages, coupled with reliability of supply, give us a distinct  competitive edge as we enter new markets.”  

Alcebíades de Mendonça Athayde Junior, Libbs Executive President, commented, “We are very happy with  this partnership that is going to make a difference in our patients’ lives. We started with Biocon Biologics  years ago, and we were very successful: our Trastuzumab became a leader in the private market, a milestone  for our company. We will now continue making a difference in people’s lives with Biocon, with the goal to  expand access to quality, safe and effective treatments to our patients.”